The Science Behind Joint XL

"The demand for new pharmaceutical, and nutraceutical products is being driven by fundamental shifts in demand for improved health and quality of life."

Click here to view the Joint Degenaration Process and how Joint XL is a highly effective natural anti-inflammatory, which is designed to not only reduce pain and inflammation, but also protects joints from breakdown associated with arthritis and other inflammatory joint conditions.

How does it work?

Joint XL reduces pain and inflammation, and protects joints from breakdown associated with arthritis and other inflammatory cartilage conditions.

Interpath has scientifically proven that the ingredients in Joint XL:

1. Significantly reduce PGE2 production*

(reduces pain and inflammation)

2. Increases cartilage cell viability and decreases the loss of GAGs from the cartilage matrix *

(reduces cartilage breakdown)

3. Inhibits Nitric Oxide Production*

(reduces the pain sensation and damaging oxidation of cell membranes within the joint)

4. Gastroprotective Function

(Components of Joint XL are known to help protect the gastro-intestinal tract and other organs)

Joint XL is a unique natural pharmaceutical with extensive independent peer reviewed scientific research proving its efficacy.

This research funded a PhD and a Masters Projects with the theses having been successfully defended. The following research papers have been submitted for peer review and have been either published or accepted for publication in journals including Molecular Nutrition and Food and the American Journal of Veterinary Research:

• Pearson, W., Orth, M.W., Karrow, N.A. and Lindinger, M.I. (2007) Anti-inflammatory and chondroprotective effects of nutraceuticals from Sashas Blend in a Cartilage Explant Model of Inflammation. Molecular Nutrition and Food Research. 51, 1020-1030.
• Pearson, W., Orth, M.W., Karrow, N.A. and Lindinger, M.I. (2008). Effects of simulated digestsof Epiitalis and a dietary nutraceutical on interlukin-1 - induced inflammatory responses in cartilage explants. American Journal of Veterinary Research.
• Pearson, W., Orth, M.W., Karrow, N.A. and Lindinger, M.I. (2009). Evaluation of Inflammatory Responses Induced via Intra-articular Injection of Interleukin - 1 in Horses Recieveing a Dietary Nutraceutical and Assessment of the Clinical Effects of Long-term Nutraceutical Administration. American Journal of Veterinary Research. Vol 70, No. 7, 2009

The following are research papers presented at two of the most prestigious equine veterinary scientific meetings held in 2008. It is a very competitive process to have papers accepted for these conferences and Interpath is proud for the researchers who received this recognition for their work. Proceedings published in association with these conferences are distributed to veterinarians around the world.

• Pearson, W., Orth, M.W., Lindinger, M.I. (2008). IL-1-induced articular inflammation in horses and modulation of inflammation by Sasha's EQ, a dietary nutraceutical. Scientific Program Presentation, American Association of Equine Practitioners 54th Annual Convention. December 6th-10th, San Diego, California.
• Pearson, W., Orth, M.W., Lindinger, M.I. (2008) Induction of Articular Inflammation in Horses Using Intra-Articular Il-1, and Modulation of Response to Il-1 by Sashas EQ, a Dietary Nutraceutical. Clinical Research Presentation, British Equine Veterinary Association Congress, 10th -13th September, 2008. Liverpool, England.

In-vitro and in-vivo findings have clearly demonstrated the products ability to:

• increase cartilage cell viability,
• suppress the loss of GAGs from the cartilage matrix,
• significantly inhibit over-production of PGE2 and Nitric Oxide
• provide the full range of GAGs essential for the synthesis of new and healthy cartilage, joints and joint fluid as well as providing chondrocyte and cell proliferation properties.

*Study conducted for Interpath at the University of Guelph (Canada)